PAH News

February 17, 2020February 17, 2020

Case Report Suggests Lack of Vitamin C as PAH Cause

News, PAH News

Vitamin C deficiency can cause pulmonary arterial hypertension (PAH), a new case report suggests, highlighting the need to test vitamin C levels in people with PAH. The report, “Vitamin ... Read more

February 10, 2020February 10, 2020

Switching to Inhaled Treprostinil Combo Safe, Effective in Stable PAH Patients, Study Suggests

News, PAH News

Switching from injectable treprostinil or epoprostenol to a combination therapy including inhaled treprostinil appears to be safe, well tolerated, and effective for a select group of patients with clinically stable ... Read more

February 7, 2020February 7, 2020

PhaseBio Reports Positive Effects of PB1046 Therapy in PAH Patient in Case Study

News, PAH News

The biopharmaceutical PhaseBio announced positive results from a case study involving a patient with pulmonary arterial hypertension (PAH) who received treatment with PB1046, a new therapy using the company’s ... Read more

February 3, 2020February 6, 2020

FDA Asked to Approve LIQ861, Treprostinil Dry Powder Inhaler for PAH, Liquidia Announces

News, PAH News

Liquidia Technologies is requesting U.S. Food and Drug Administration (FDA) approval of LIQ861, an inhaled dry powder formulation of the vasodilator treprostinil, to treat pulmonary arterial hypertension (PAH). The request came in ... Read more

January 31, 2020January 31, 2020

Sotatercept Eases Heart Strain, Improves Exercise Capacity in PAH, Trial Shows

News, PAH News

Treatment with sotatercept (ACE-011) eased heart strain and improved exercise capacity in individuals with pulmonary arterial hypertension (PAH) participating in the Phase 2 PULSAR trial, according to Acceleron Pharma, the ... Read more

January 29, 2020January 29, 2020

Alembic Pharmaceuticals’ Bosentan Tablets, Generic to Tracleer, Approved by the FDA

News, PAH News

A new generic version of Actelion’s Tracleer (bosentan), developed by Alembic Pharmaceuticals, has been approved by the U.S. Food and Drug Administration (FDA) for treating pulmonary arterial hypertension (PAH). The approval comes after Alembic ... Read more

January 17, 2020January 17, 2020

Circular RNA Molecule May Help Diagnose, Predict Clinical Outcomes in IPAH, Study Suggests

News, PAH News

Levels of a circular RNA molecule in the blood could help diagnose and predict the clinical outcomes of those with idiopathic pulmonary arterial hypertension (IPAH), a study suggests. The ... Read more

January 13, 2020January 13, 2020

Orenitram Slows PAH Progression When Used With Other Therapies, Phase 3 Trial Finds

News, PAH News

Orenitram (treprostinil tablets) reduced clinical worsening and slowed disease progression in people with pulmonary arterial hypertension (PAH) who had recently begun treatment with an alternative approved therapy, a Phase ... Read more

January 10, 2020January 22, 2020

AI Therapeutics Seeks Partner to Advance Testing of LAM-001, its Candidate Inhaled Therapy for PAH

News, PAH News

AI Therapeutics is seeking to advance the development of its candidate treatment LAM-001 for patients with lymphangioleiomyomatosis (LAM) and pulmonary arterial hypertension (PAH), two rare lung disorders. Specifically, the ... Read more

January 6, 2020January 6, 2020

Acceleron Pharma and Fulcrum Therapeutics Partner to Find Small Molecule Treatments

News, PAH News, PH News

Acceleron Pharma and Fulcrum Therapeutics are working together to discover small molecules that can be used to treat pulmonary diseases, including pulmonary hypertension (PH). Under this collaboration, Acceleron will ... Read more

Pin It on Pinterest